Positron Appoints Charles Conroy As Chief Operati... ( CHICAGO Nov. 15 2012 /- Positron Corp...)

Positron Appoints Charles Conroy As Chief Operating Officer

Date:11/15/2012

CHICAGO, Nov. 15, 2012 /PRNewswire/ -- Positron Corporation (OTCBB:POSC), a nuclear medicine healthcare company, announced today the appointment of Charles Conroy as Chief Operating Officer.

Conroy's background includes extensive experience in corporate & product strategy, partner & alliance management, licensing, acquisitions, divestitures and portfolio management. During his career, Conroy has led highly successful global business development, marketing, and operations initiatives for companies including Covidien, Eli Lilly, and Amerinet. Conroy earned a Bachelor of Science in Pharmacy from Purdue University and a Master of Business Administration from the University of Michigan.

As COO, Conroy will define and implement strategies focused on accelerating growth across the company's product portfolio. Conroy joins Positron's clinical and technical executive team, consisting of: Joseph Oliverio (PET), Jason Kitten (Radiopharmaceutical/Radioisotope Production) and Scott Stiffler (Pharmaceutical Automation/Product Development). Conroy will also lead the Company's sales and marketing initiatives; focusing on revenue generation, enhancing Positron's industry position and brand recognition as a leader in nuclear medicine.

Conroy commented, "I am very excited to be joining the Positron team. As the only company with a full nuclear cardiology solution, Positron is well positioned to take a leadership role in the nuclear medicine industry. The caliber of the team and the company's reputation coupled with its strong sense of purpose make this a tremendous opportunity."

"Chuck's leadership, expertise and background of implementing an integrated global sales and marketing plan adds tremendous value in executing Positron's objectives," stated Patrick G. Rooney, Chief Executive Officer of Positron. "Chuck's approach and track record will greatly complement the knowledge and direction provided by each member of our exe
'/>"/>

SOURCE Positron Corporation
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Positron Consolidates Radiopharmaceutical & Radioisotope Facilities
2. Positrons Attrius PET Scanner Now Utilized In Alzheimers Imaging With Amyvid Agent
3. Neusoft Positron Medical Systems Receives ISO Certification and CE Mark for their Attrius PET System
4. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
5. Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer
6. Nephros Appoints John C. Houghton as President and Chief Executive Officer
7. Elsevier Appoints New President of Elsevier CPM Resource Center
8. GenWay Biotech Appoints New Vice President of Custom/OEM
9. Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales
10. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
11. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland

Post Your Comments:

(Date:5/21/2013)... , May 21, 2013 Vasomedical, Inc. (OTC BB: ... the design, manufacture and sale of medical devices and in ... Dr. Jun Ma , President and CEO ... LLP MicroCap Conference on Thursday, May 30, 2013 in ... Hotel. The Company,s presentation is scheduled to ...

(Date:5/21/2013)... 21, 2013 Reportlinker.com announces that ... in its catalogue: ... Optical Coherence Tomography (OCT) ... OBJECTIVES BCC,s ... offer synopsis of the current and future ...

(Date:5/21/2013)... Fla. , May 21, 2013 Janssen ... safety results from the global Phase 3 PROMISE ... inhibitor simeprevir (TMC435) led to sustained virologic response ... in 79 percent of treatment-experienced genotype 1 chronic ... including all stages of liver fibrosis, when administered ...

[0] Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference [0] Global Markets and Technologies for Optical Coherence Tomography (OCT)[0] Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients

... , , BERLIN ... NKTR ) presented favorable data today on lead oncology program, ... investigational compound in ovarian cancer. These data were presented at ... Oncology (ESMO) 2009 Joint Multidisciplinary Congress in Berlin, Germany. , ...

... , , , ... a Phase II trial of regorafenib (BAY 73-4506), a potent oral multi-kinase ... partial response rate and 50 percent stabilization rate in patients with metastatic ... at the joint 15th Congress of the European CanCer Organisation and 34th ...

Cached Medicine Technology:NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 2 NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 3 NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 4 NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 5 Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 2 Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 3 Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 4

NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients

(Date:5/21/2013)... 21, 2013 Heritage Woods of Dwight ... affordable assisted living community, is hosting a Quality Home Health ... 2 p.m. on Tuesday, May 28. , The community, which ... older adults of all incomes, including those on Medicaid, who ... program is open to the public. There is no ...

(Date:5/21/2013)... the George Washington (GW) University School of ... the launch of the Avance Center for ... between SPHHS, the Maryland Multicultural Youth Centers, ... This university-community partnership aims to address public ... through research, mutual capacity building and prevention ...

(Date:5/21/2013)... 2013 Patients of Dr. Michael Shenk and ... teeth due to gum disease and would like permanent tooth ... treatment with laser gum surgery. Gum disease must ... success rate out of all tooth replacement options. , ... new procedure cleared by the Food and Drug Administration (FDA) ...

(Date:5/21/2013)... LEAWOOD, Kan. Primary care practice transformation on ... health care reform efforts aimed at achieving better ... Amid emerging evidence that transformation toward the patient-centered ... today,s health care environment, the U.S. Department of ... and Quality funded 14 studies to learn more ...

(Date:5/21/2013)... York (PRWEB) May 21, 2013 Parker ... the rights of victims injured by defective medical devices, ... Bone & Joint Surgery on May 15, 2013. The ... used to identify complications that occur in patients with ... of failure. ( http://www.jbjs.org/article.aspx?articleid=1684770 ) , ...

Breaking Medicine News(10 mins):Health News:Heritage Woods of Dwight Affordable Assisted Living to Host Informational Program on the Do's and Don'ts of Arthritis 2 Health News:GW launches center to address health disparities in the Latino immigrant community 2 Health News:GW launches center to address health disparities in the Latino immigrant community 3 Health News:Shenk Dental Care Stimulates Bone Growth for Gum Disease Patients Seeking Dental Implants with Laser Gum Surgery in Atlanta, GA 2 Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 2 Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 3 Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 4 Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 5 Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 6 Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2 Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3

[0] Heritage Woods of Dwight Affordable Assisted Living to Host Informational Program on the Do's and Don'ts of Arthritis [0] GW launches center to address health disparities in the Latino immigrant community [0] Shenk Dental Care Stimulates Bone Growth for Gum Disease Patients Seeking Dental Implants with Laser Gum Surgery in Atlanta, GA [0] AHRQ-funded journal supplement offers lessons on primary care practice transformation [0] Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants

... Mass., Jan. 3 Boston Scientific,Corporation (NYSE: ... upcoming JP,Morgan Health Care Conference, in San Francisco., ... a 25-minute,presentation on Wednesday, January 9th, beginning at ... Executive Vice President,and Chief Financial Officer will join ...

... new retrospective study on the effects of N-acetylcysteine ... caused by acetaminophen poisoning has found that the ... higher incidence of liver recovery, and better survival ... issue of Liver Transplantation, a journal by John ...

... no raised risk to heart , , THURSDAY, Jan. 3 ... but controversial treatment for prostate cancer reduces long-term death ... as some specialists had feared. , In patients ... testosterone-lowering drugs and radiation therapy appeared to lower the ...

... ... issued, PARAMUS, N.J., Jan. ... forcing the conversion of its Series A,Convertible Preferred Stock. At 5:00 p.m., ... of common stock. All of the issued and outstanding shares of Series,A ...

... Insulet Corporation,(Nasdaq: PODD ), the manufacturer and ... that Duane DeSisto, Chief Executive,Officer, will participate in ... scheduled to present an overview of the Company,at ... 2008 at The Westin St.,Francis Hotel in San ...

... is a former Officer of Aetna, Inc., ... HSKA ) today announced that Ms. Louise McCormick ... http://www.newscom.com/cgi-bin/prnh/20000622/HESKALOGO ), "We pride ourselves on ... Board consisting of high quality, independent Directors,is critical ...

Cached Medicine News:Health News:Boston Scientific to Participate in JP Morgan Health Care Conference 2 Health News:Treatment with NAC is associated with better outcomes for children with liver failure 2 Health News:Combo Therapy Cuts Prostate Cancer Death Rates 2 Health News:Combo Therapy Cuts Prostate Cancer Death Rates 3 Health News:Smart Balance Announces Conversion of Convertible Preferred Stock 2 Health News:Louise McCormick Joins Heska's Board of Directors 2 Health News:Louise McCormick Joins Heska's Board of Directors 3

Boston Scientific to Participate in JP Morgan Health Care Conference Treatment with NAC is associated with better outcomes for children with liver failure Combo Therapy Cuts Prostate Cancer Death Rates Smart Balance Announces Conversion of Convertible Preferred Stock Insulet Corporation to Present at the JPMorgan Healthcare Conference on January 8, 2008 Louise McCormick Joins Heska's Board of Directors

... The CritSpin whisper quiet, compact system ... clinic anywhere fast, accurate and cost effective ... Digital Reader, the CritSpin System offers a ... spin, complete cell packing - Meets NCCLS ...

... light over one smooth pulse duration, rather ... damage skin) that other technologies use. Palomar's ... water supply through the StarLux handpiece, down ... to as low as 4 degrees C. ...

Used to provide drainage of urine from the bladder. All-silicone construction provides maximum softness and biocompatibility for enhanced patient comfort. Supplied sterile in peel-open packages. Inte...

Used for stenting the urethra during hypospadias or epispadias repair and to promote postoperative drainage of the bladder. Supplied sterile in peel-open packages. Intended for one-time use....

Medicine Products:

CritSpin Microhematocrit Centrifuge StarLux Pulsed Light and Laser System Silicone Foley Silicone Universal Drainage Stents